keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma CNS

keyword
https://www.readbyqxmd.com/read/30528416/intrathecal-central-nervous-system-prophylaxis-in-patients-with-diffuse-large-b-cell-lymphoma-at-an-academic-healthcare-system
#1
Kevin H Hall, Kelly Valla, Christopher R Flowers, Jonathon B Cohen
INTRODUCTION: Intrathecal chemoprophylaxis is often administered to patients with diffuse large B-cell lymphoma (DLBCL) to lower the rates of central nervous system (CNS) relapse, although its benefit has not been well-described. Prognostic models, including the CNS-International Prognostic Index (IPI), have been developed to aid in identifying patients at highest risk for CNS relapse. PATIENTS AND METHODS: We evaluated 112 patients diagnosed with DLBCL from 2009 to 2016 at Emory Healthcare and classified them as high (n = 44) or low risk (n = 68) for CNS relapse and compared CNS prophylaxis rates and relapse rates between groups...
November 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/30523619/aids-associated-malignancies
#2
Ramya Vangipuram, Stephen K Tyring
Malignancies were one of the earliest recognized manifestations that led to the description of the acquired immune deficiency syndrome (AIDS). The majority of cancers in AIDS patients are associated with coinfection with oncogenic viruses, such as Epstein-Barr virus, human herpesvirus 8, and human papillomavirus, with resulting malignancies occurring secondary to diminished immune surveillance against viruses and virus-infected tumor cells. Over 50% of AIDS lymphomas are associated with Epstein-Barr virus (EBV) and/or HHV8 infection...
2019: Cancer Treatment and Research
https://www.readbyqxmd.com/read/30516868/role-of-systemic-high-dose-methotrexate-and-combined-approaches-in-the-management-of-vitreoretinal-lymphoma-a-single-center-experience-1990-2018
#3
Alessia Castellino, Jose S Pulido, Patrick B Johnston, Kay M Ristow, N Nora Bennani, David J Inwards, William R Macon, Ivana N M Micallef, Rebecca L King, Diva R Salomao, Thomas E Witzig, Thomas M Habermann, Grzegorz S Nowakowski
Vitreoretinal lymphoma (VRL) management remains a challenge. We present 72 patients with VRL, diagnosed at Mayo Clinic between 1990-2018. Three nondiffuse large B-cell lymphoma (DLBCL) histology cases were excluded. Among 69 DLBCL, 33 patients had primary VRL (PVRL), 18 concurrent intraocular and central nervous system (CNS) or systemic disease and 18 secondary VRL. Patients received intraocular chemotherapy (intraocular injections of rituximab or metothrexate or steroids or in combination), radiotherapy, systemic or combined systemic plus intraocular treatment in 9, 10, 35, and 15 cases, respectively...
December 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30514094/annals-express-autotaxin-and-sil-2r-levels-in-cerebrospinal-fluids-are-useful-for-the-diagnosis-of-central-nervous-system-invasion-caused-by-hematological-malignancies
#4
Takuya Shimura, Makoto Kurano, Yoshifumi Morita, Naoyuki Yoshikawa, Masako Nishikawa, Koji Igarashi, Satoshi Shimamoto, Junken Aoki, Yutaka Yatomi
BACKGROUND: Invasion of the central nervous system (CNS) by hematological malignancies is diagnosed by cytological analyses of cerebrospinal fluid (CSF) or diagnostic imaging, while quantitative biomarkers for CNS invasion are not available and needed to be developed. Methods; In this study, we measured the levels of autotaxin (ATX) and soluble IL-2 receptor (sIL-2R) in cerebrospinal fluid (CSF) and evaluated their usefulness as biomarkers for CNS invasion. RESULTS: We observed that both the ATX and sIL-2R levels in CSF were higher in subjects with CNS invasion than in those without, and the CSF levels were independent from the serum levels of these biomarkers...
December 4, 2018: Annals of Clinical Biochemistry
https://www.readbyqxmd.com/read/30502843/cerebrospinal-fluid-interleukin-il-10-and-il-10-il-6-ratio-as-biomarkers-for-small-b-cell-lymphoproliferations-with-leptomeningeal-dissemination
#5
Myrto Costopoulos, Rathana Kim, Sylvain Choquet, Karim Maloum, Caroline Houillier, Caroline Algrin, Catherine Settegrana, Juliette Villemonteix, Martine Brissard, Claire Quiney, Sophie Bernard, Frederic Davi, Catherine Thieblemont, Khe Hoang-Xuan, Veronique Leblond, Helene Merle-Beral, Magali Le Garff-Tavernier
We here report for the first time that low levels of interleukin (IL)-10 do not exclude lymphomatous meningitis (LM) in B-cell lymphoproliferative disorders (CLPD). Unexpectedly, IL-10 levels and IL-10:IL-6 ratio in CLPD differed from the levels observed in diffuse large B-cell lymphoma (DLBCL). We report the usefulness of adding the IL-10:IL-6 ratio in order to potentially reveal more aggressive lymphomas: either a transformation or an association with another "hidden" lymphoma such as primary CNS lymphoma (PCNSL)...
October 2018: Seminars in Hematology
https://www.readbyqxmd.com/read/30502564/primary-cns-lymphoma-patient-derived-orthotopic-xenograft-model-capture-the-biological-and-molecular-characteristics-of-the-disease
#6
Frédéric Pouzoulet, Agusti Alentorn, Louis Royer-Perron, Franck Assayag, Karima Mokhtari, Dalila Labiod, Magali Le Garff-Tavernier, Mailys Daniau, Emmanuelle Menet, Matthieu Peyre, Anne Schnitzler, Justine Guegan, Frédéric Davi, Khê Hoang-Xuan, Carole Soussain
Primary CNS lymphomas (PCNSL) are rare and poor prognosis diffuse large B-cell lymphomas. Because of the brain tumor environment and the restricted distribution of drugs in the CNS, specific PCNSL patient-derived orthotopic xenograft (PDOX) models are needed for preclinical research to improve the prognosis of PCNSL patients. PCNSL patient specimens (n = 6) were grafted in the caudate nucleus of immunodeficient nude mice with a 83% rate of success, while subcutaneous implantation in nude mice of human PCNSL sample did not generate lymphoma, supporting the role of the brain microenvironment in the PCNSL physiopathology...
November 16, 2018: Blood Cells, Molecules & Diseases
https://www.readbyqxmd.com/read/30501868/dose-adjusted-epoch-r-etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin-and-rituximab-in-untreated-aggressive-diffuse-large-b-cell-lymphoma-with-myc-rearrangement-a-prospective-multicentre-single-arm-phase-2-study
#7
Kieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, Ariela Noy, Paolo Fabrizio Caimi, Stefania Pittaluga, Samir Parekh, Ann Lacasce, John W Hayslip, Deepa Jagadeesh, Sunil Nagpal, Mary Jo Lechowicz, Rakesh Gaur, Andrea Lucas, Christopher Melani, Mark Roschewski, Seth M Steinberg, Elaine S Jaffe, Brad Kahl, Jonathan W Friedberg, Richard F Little, Nancy L Bartlett, Wyndham H Wilson
BACKGROUND: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment...
December 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30500594/experience-with-102-frameless-stereotactic-biopsies-using-the-neuromate%C3%A2-robotic-device
#8
Hamzah Yasin, Hans-Joachim Hoff, Ingmar Blümcke, Matthias Simon
OBJECTIVE: Stereotactic biopsy is a standard procedure in neurosurgery. In addition to or even replacing frame-based stereotaxy some centers also utilize frameless imaging-based techniques and more recently robotic systems. Here we report a retrospective analysis of our experience with 102 consecutive biopsies performed in our institution using the neuromate® robotic device. METHODS: Between March 2013 and April 2018, 102 robot-assisted frameless biopsies were performed in 100 consecutive patients (median age/ range: 66/ 7-86 yrs...
November 27, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/30500103/hepatosplenic-t-cell-lymphoma-in-an-immunocompetent-male-with-central-nervous-system-invasion-a-rare-clinical-entity
#9
Fan Wu, Ying Pan, Huiping Wang, Qianshan Tao, Furun An, Jiakui Zhang, Zhimin Zhai
Hepatosplenic T-cell lymphoma (HSTCL) is a very rare non-Hodgkin lymphoma with an aggressive clinical course and poor prognosis. Patients of this disease usually presented with hepatosplenomegaly, which can be misdiagnosed or delayed. Bone marrow (BM) and peripheral blood (PB) are frequently involved, however, central nervous system (CNS) involvement is less common. Here, we are reporting an unusual case of hepatosplenic γδ T-cell lymphoma in a 64-year-old man with CNS involvement. Flow cytometry immunophenotyping was proved of great diagnostic contribution...
November 30, 2018: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/30499908/factors-influencing-do-not-resuscitate-status-in-children-during-last-month-of-life-single-institution-experience
#10
Bilal Moaed, Oz Mordechai, Myriam Weyl Ben-Arush, Sharon Tamir, Ruth Ofir, Sergey Postovsky
BACKGROUND: It is currently expected that about 20% of children with cancer will ultimately die. Writing advanced life directives sufficiently long before the actual death of a child ensues allows both parents and medical staff to develop optimal treatment plans in the best interests of the child. AIM OF THE STUDY: The aim of the study was to evaluate factors that may influence the process of decision-making regarding Do-Not-Resuscitate (DNR) status. METHODS: Retrospective single institution study...
November 28, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/30486745/altered-methotrexate-clearance-in-the-treatment-of-cns-lymphoma-with-concurrent-use-of-nitrofurantoin-for-a-urinary-tract-infection
#11
Jasmine L Gowarty, Ina J Patel, Jon D Herrington
Methotrexate is a widely used chemotherapy agent with a propensity for drug interactions placing the patient at risk for toxicities. There are several modes for altering methotrexate clearance including concomitant drugs leading to toxic effects on the kidneys, medications producing an acidic urine pH, and agents interfering with methotrexate transporters including the organic anion transporter and breast cancer resistance protein efflux pump. We report a case of a patient with central nervous system non-Hodgkin's lymphoma receiving high-dose methotrexate and being concomitantly treated for a urinary tract infection with nitrofurantoin...
November 28, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/30474103/role-of-temozolomide-in-the-treatment-of-cancers-involving-the-central-nervous-system
#12
REVIEW
Karisa C Schreck, Stuart A Grossman
Temozolomide has been available to oncologists for over 30 years. During this time, it has become an integral part of standard therapy in patients with high-grade gliomas. Given its ability to traverse the blood-brain barrier, temozolomide has also been evaluated in other cancers that involve the central nervous system (CNS). We review its role in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers. There is strong evidence that temozolomide is effective in patients with high-grade astrocytomas and oligodendrogliomas...
November 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30471148/efficacy-of-the-gmall-b-all-nhl2002-protocol-in-burkitt-leukaemia-lymphoma-and-aggressive-non-hodgkin-lymphomas-with-or-without-cns-involvement
#13
Maria Sakarou, Lewin Eisele, Ulrich Dührsen, Andreas Hüttmann
OBJECTIVES: The GMALL-B-ALL/NHL2002 protocol is effective in Burkitt-lymphoma/leukaemia (BL). Its role in other aggressive lymphomas and in patients with simultaneous central nervous system (CNS) and peripheral involvement is unclear. METHODS: This is a retrospective outcome analysis in 76 patients with BL (n=26), B-lymphoblastic lymphoma (B-LBL; n=3), diffuse large B-cell lymphoma (DLBCL; n=31), mantle-cell lymphoma (MCL; n=6), transformed B-cell non-Hodgkin lymphomas (tB-NHL; n=7) and T-cell NHL (T-NHL; n=3) treated with the GMALL-B-ALL/NHL2002 protocol...
November 24, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/30423172/introduction-of-novel-agents-in-the-treatment-of-primary-cns-lymphoma
#14
Christian Grommes, Lakshmi Nayak, Han W Tun, Tracy T Batchelor
Novel insights into the pathophysiology of Primary Central Nervous System Lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting...
November 13, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/30418592/comprehensive-approach-to-diagnosis-and-treatment-of-newly-diagnosed-primary-cns-lymphoma
#15
Christian Grommes, James L Rubenstein, Lisa M DeAngelis, Andres J M Ferreri, Tracy T Batchelor
Primary central nervous system (CNS) lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved mainly due to the introduction and wide-spread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens...
November 12, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/30416076/temporal-patterns-in-the-risk-of-chronic-health-conditions-in-survivors-of-childhood-cancer-diagnosed-1970-99-a-report-from-the-childhood-cancer-survivor-study-cohort
#16
Todd M Gibson, Sogol Mostoufi-Moab, Kayla L Stratton, Wendy M Leisenring, Dana Barnea, Eric J Chow, Sarah S Donaldson, Rebecca M Howell, Melissa M Hudson, Anita Mahajan, Paul C Nathan, Kirsten K Ness, Charles A Sklar, Emily S Tonorezos, Christopher B Weldon, Elizabeth M Wells, Yutaka Yasui, Gregory T Armstrong, Leslie L Robison, Kevin C Oeffinger
BACKGROUND: Treatments for childhood cancer have evolved over the past 50 years, with the goal of maximising the proportion of patients who achieve long-term survival, while minimising the adverse effects of therapy. We aimed to assess incidence patterns of serious chronic health conditions in long-term survivors of childhood cancer across three decades of diagnosis and treatment. METHODS: We used data from the Childhood Cancer Survivor Study, a retrospective cohort with longitudinal follow-up of 5-year survivors of common childhood cancers (leukaemia, tumours of the CNS, Hodgkin lymphoma, non-Hodgkin lymphoma, Wilms tumour, neuroblastoma, soft tissue sarcoma, or bone tumours) who were diagnosed before the age of 21 years and from 1970 to 1999 in North America...
November 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30405921/west-nile-encephalitis-an-unusual-infection-in-a-chronic-lymphocytic-leukemia-patient
#17
Manuel R Espinoza-Gutarra, Sherri L Cervantez, Zohra Nooruddin
CNS involvement by CLL is a rare occurrence, usually happening in the context of a transformation to a more aggressive lymphoma in what is known as Richter's transformation. We report a patient with active CLL who developed confusion and was found to have West Nile encephalitis that initially mimicked CNS involvement by CLL. The patient recovered with supportive treatment and later restarted ibrutinib therapy. This case illustrates the importance of maintaining a broad differential among cancer patients with new onset confusion as well as that of questioning malignant infiltration of CNS when there is concomitant active CNS infection...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/30397742/management-and-survival-trends-for-adult-patients-with-malignant-gliomas-in-the-setting-of-multiple-primary-tumors-a-population-based-analysis
#18
Ha Son Nguyen, Ninh B Doan, Michael Gelsomino, Saman Shabani, Ahmed J Awad, Mayank Kaushal, Martin M Mortazavi
INTRODUCTION: The impact of multiple primary tumors, in the setting of malignant glioma (MG), has not been heavily explored. METHODS: We extracted demographics and clinical data from the SEER-18 registry for adult patients with MGs. The cases were separated based on the sequence of MG diagnosis relative to the other primary tumors: Group (A) One primary only or first primary of multiple primaries and Group (B) second primary or subsequent primary tumor. Incidences, frequencies, and glioma-related survivals were analyzed...
November 5, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/30390359/cd79b-mutations-in-primary-vitreoretinal-lymphoma-diagnostic-and-prognostic-potential
#19
Ichiro Yonese, Hiroshi Takase, Mayumi Yoshimori, Erika Onozawa, Akiho Tsuzura, Tohru Miki, Manabu Mochizuki, Osamu Miura, Ayako Arai
OBJECTIVE: Primary vitreoretinal lymphoma (PVRL) is a rare type of lymphoma wherein the lesions are limited to the eyes. PVRL is difficult to diagnose because of the challenges related to obtaining sufficient samples for biopsy. Moreover, PVRL has poor outcomes and often leads to the development of central nervous system (CNS) lesions during its course. Two studies recently reported that approximately 70%-80% of patients with vitreoretinal lymphoma have MYD88L265P , which is frequently mutated in primary CNS lymphoma (PCNSL)...
November 2, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/30370365/response-adapted-radiation-therapy-for-newly-diagnosed-primary-diffuse-large-b-cell-lymphoma-of-the-cns-treated-with-methotrexate-based-systemic-therapy
#20
Tommy Sheu, Sarah A Milgrom, Therese Y Andraos, Jillian R Gunther, Linda Chi, Loretta Nastoupil, Nathan Fowler, Yasuhiro Oki, Michelle A Fanale, Luis E Fayad, Fredrick Hagemeister, Sattva S Neelapu, L Jeffrey Medeiros, Chitra Hosing, Yago Nieto, Sairah Ahmed, Amin M Alousi, Bouthaina Dabaja, Chelsea C Pinnix
Background: For patients with primary diffuse large B-cell lymphoma of the central nervous system (PCNSL), whole-brain radiation therapy (WBRT) to doses of ≥45 Gy are often given after a partial response (PR) to methotrexate-based induction chemotherapy. We conducted an exploratory analysis to determine whether lower-dose WBRT, given with a boost to sites of persistent disease, might be a reasonable alternative. Methods and materials: We retrospectively reviewed the records of 22 patients with PCNSL who received WBRT, with or without a boost, after methotrexate-based induction chemotherapy...
October 2018: Advances in Radiation Oncology
keyword
keyword
171665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"